首页> 外文期刊>European Journal of Pharmacology: An International Journal >Meta-chlorophenylpiperazine induced changes in locomotor activity are mediated by 5-HT1 as well as 5-HT2C receptors in mice.
【24h】

Meta-chlorophenylpiperazine induced changes in locomotor activity are mediated by 5-HT1 as well as 5-HT2C receptors in mice.

机译:在小鼠中,间氯苯基哌嗪诱导的运动活性变化是由5-HT1和5-HT2C受体介导的。

获取原文
获取原文并翻译 | 示例
           

摘要

1-(Meta-chloro)phenylpiperazine (m-CPP) is a 5-HT receptor agonist which has been purported to be relatively selective for the 5-HT2C receptor. In particular, the hypolocomotion produced by m-CPP has been suggested to be mediated by 5-HT2C receptors. m-CPP binds with high affinity to 5-HT1 as well as 5-HT2 receptors, thus effects of m-CPP on locomotor activity may be due to the physiologic summation of the actions of m-CPP at 5-HT1 as well as 5-HT2 receptors. The present study investigated the effects of m-CPP alone and in the presence of the 5-HT2 receptor antagonist 6-methyl-1-(-methyethyl)-ergoline-8beta-carboxylic acid 2-hydroxy-1-methylpropyl ester maleate (LY53857), the 5-HT1A receptor antagonist N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]-ethyl]-N-(2pyridinyl)c yclohexanecarboxamide trihydrochloride (WAY 100,635), and the 5-HT(1B/1D) receptor antagonist 2'-methyl-4'-(5-methyl-[1,2,4]oxadiazol-3-yl)-biphenyl-4-corbox ylic acid [4-methoxy-3-(4-methyl-piperazin-1-yl)-phenyl]amide (GR 127935) on locomotor activity. Administration of m-CPP alone (0.3-10 mg/kg) produced a dose-related decrease in locomotor activity. The 5-HT(1B/1D) receptor antagonist GR 127935 (3.0 mg/kg) in combination with m-CPP produced a slight leftward shift of the dose-response curve of m-CPP. The 5-HT1A receptor antagonist WAY 100,635 (1.0 mg/kg) in combination with m-CPP did not alter the m-CPP dose-response curve. The non-selective 5-HT2 receptor antagonist LY53857 (1.0 mg/kg) in combination with m-CPP unmasked a hyperlocomotion produced by m-CPP. Furthermore, the hyperlocomotion produced by m-CPP in the presence of LY53857 (1.0 mg/kg) was blocked by both the 5-HT(1B/1D) receptor antagonist GR 127935 (3.0 mg/kg) and the 5-HT1A receptor antagonist WAY 100,635 (1.0 mg/kg). The present results demonstrate that the hyperlocomotion seen with the combination of m-CPP and LY53857 is mediated by 5-HT1 receptors. Taken together the data indicate that m-CPP affects locomotor activity by the physiologic summation of agonist activity at the 5-HT2C receptor as well as the 5-HT1 receptor family.
机译:1-(间氯)苯基哌嗪(m-CPP)是一种5-HT受体激动剂,据称对5-HT2C受体具有相对选择性。特别地,已经提出了由m-CPP产生的运动不足是由5-HT 2C受体介导的。 m-CPP与5-HT1和5-HT2受体具有很高的亲和力,因此m-CPP对运动活性的影响可能是由于m-CPP在5-HT1以及5处的生理作用所致-HT2受体。本研究调查了单独的m-CPP以及在5-HT2受体拮抗剂6-甲基-1-(-甲基乙基)-麦角灵8β-羧酸2-羟基-1-甲基丙基马来酸酯(LY53857 ),5-HT1A受体拮抗剂N- [2- [4-(2-甲氧基苯基)-1-哌嗪基]-乙基] -N-(2-吡啶基)c环己烷甲酰胺三盐酸盐(WAY 100,635)和5-HT(1B / 1D)受体拮抗剂2'-甲基-4'-(5-甲基-[1,2,4]恶二唑-3-基)-联苯-4-可乐果酸[4-甲氧基-3-(4-甲基-哌嗪-1-基)-苯基]酰胺(GR 127935)对运动活性的影响。单独施用m-CPP(0.3-10 mg / kg)导致运动活动剂量相关性降低。 5-HT(1B / 1D)受体拮抗剂GR 127935(3.0 mg / kg)与m-CPP结合产生了m-CPP剂量-反应曲线的轻微左移。 5-HT1A受体拮抗剂WAY 100,635(1.0 mg / kg)与m-CPP结合使用不会改变m-CPP的剂量反应曲线。非选择性5-HT 2受体拮抗剂LY53857(1.0 mg / kg)与m-CPP的结合掩盖了m-CPP产生的超运动。此外,5-HT(1B / 1D)受体拮抗剂GR 127935(3.0 mg / kg)和5-HT1A受体拮抗剂均能阻止LY53857(1.0 mg / kg)存在时m-CPP产生的超运动WAY 100,635(1.0 mg / kg)。本结果表明,由m-CPP和LY53857组合出现的超运动是由5-HT1受体介导的。数据合计表明,m-CPP通过对5-HT2C受体和5-HT1受体家族的激动剂活性进行生理累加来影响运动活性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号